Comparison of Postoperative GI motility Recovery According to the Types of Neuromuscular blockade reversal agent

Effects on Postoperative Gastrointestinal Motility after Neuromuscular Blockade Reversal with Sugammadex versus pyridostigmine/Glycopyrrolate in Laparoscopic cholecystectomy patient

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0004330

Enrollment

100

Registered

2019-10-16

Start date

2019-02-14

Completion date

Unknown

Last updated

2019-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : For NMB reversal, intravenously inject the patients with one of the two NMB reversal agents, i.e., sugammadex 2 mg/kg (Group experimental drug) or pyridostigmine 0.2 mg/kg and glycopyrrolate 0.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: American Society of Anesthesiologists (ASA) physical status I or II.

Exclusion criteria

Exclusion criteria: Patients requiring emergency care due to their inability to control nothing by mouth (NPO) fasting time, and those diagnosed with diabetes, ulcerative colitis, or Crohn’s disease, all of which can affect patients’ GI motility. Patients with renal dysfunction were also excluded

Design outcomes

Primary

Measure	Time frame
The data on the time elapsed between the injection of NMB reversal agents and the first gas out and defecation	—

Secondary

Measure	Time frame
Any adverse effects (such as nausea, vomiting, and dry mouth), as well as the types of stools	—

Countries

Korea, Republic of

Contacts

Public ContactHeeyun Noh

Daegu Fatima Hospital

heeyuny@naver.com+82-53-940-7434

Outcome results